Kester Capital Acquires EMAS Pharma (carve-out from Bionical Emas)

New Mountain Capital Acquires Emmes from Behrman Capital

June 21, 2022

Healthcare Services

Affiliates of New Mountain Capital have agreed to acquire Emmes, a global clinical research organization, from Behrman Capital and Emmes' other investors. The transaction, expected to close in early July 2022, positions Emmes for its next phase of growth with additional investment to expand its commercial, global and eClinical technology capabilities; terms were not disclosed.

Emmes Acquires Essex Management

March 21, 2023

Healthcare Services

Emmes, a global full-service clinical research organization, acquired Essex Management, a bioinformatics and health information technology consultancy, to enhance Emmes' data, bioinformatics and HIT capabilities. The acquisition adds more than 100 employees and expands Emmes' ability to serve government, academic and biopharma clients, including continued support for the National Cancer Institute.

Emmes Acquires UK-Based Orphan Reach

May 11, 2021

Healthcare Services

Emmes, a global full-service CRO and portfolio company of Behrman Capital, acquired Orphan Reach, a UK-based CRO specialized in rare-disease clinical research. The add-on expands Emmes' geographic footprint and rare-disease capabilities; Orphan Reach's founder and management will remain in place and financial terms were not disclosed.

BioCryst Pharmaceuticals Acquires Astria Therapeutics

January 26, 2026

Biotechnology

BioCryst Pharmaceuticals has completed its acquisition of Astria Therapeutics for an implied transaction value of approximately $700 million, financed with cash on hand and a ~$396.6 million facility provided by funds managed by Blackstone plus ~37.3 million BioCryst shares issued to Astria equity holders. The deal adds Astria's Phase 3 long-acting plasma kallikrein inhibitor navenibart to BioCryst's hereditary angioedema (HAE) portfolio and provides Astria's early-stage atopic dermatitis program (STAR0310) for which BioCryst will pursue strategic alternatives.

Ocorian Acquires Emphasys Technologies

March 8, 2021

Financial Services

Ocorian has acquired US-based capital markets service provider Emphasys Technologies, with the agreement reached on 4 March 2021 and completion expected later in March 2021. The deal gives Ocorian a presence in the United States and strengthens its capital markets and technology-enabled service offering to financial institutions.

Emmes Acquires Neox

December 30, 2020

Healthcare Services

The Emmes Company, a Behrman Capital portfolio company, has acquired Prague-headquartered CRO Neox S.R.O., an add-on that expands Emmes' BioPharma capabilities and Central/Eastern European presence. Financial terms were not disclosed; Neox brings over 150 employees and operations across multiple European countries, and founders Pavel and Petr Marek will remain in leadership roles.